Wesana Health Holdings Inc. (WSNAF)
USD 0.04
(135.29%)
USD 0.04
(135.29%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 206.21 Thousand USD | 236.34% |
| 2022 | -151.25 Thousand USD | 97.45% |
| 2021 | -5.93 Million USD | -368.19% |
| 2020 | -1.26 Million USD | -351.37% |
| 2019 | -280.65 Thousand USD | 31.68% |
| 2018 | -410.78 Thousand USD | -4898.67% |
| 2017 | -8217.95 USD | -33.39% |
| 2016 | -6161.05 USD | -139.74% |
| 2015 | -2569.85 USD | 91.31% |
| 2014 | -29.57 Thousand USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 186.92 Thousand USD | 304.23% |
| 2024 Q1 | 46.24 Thousand USD | -77.58% |
| 2023 Q4 | 206.21 Thousand USD | 20.38% |
| 2023 Q2 | 89.32 Thousand USD | 168.18% |
| 2023 Q3 | 171.31 Thousand USD | 91.78% |
| 2023 Q1 | -131.01 Thousand USD | 13.38% |
| 2023 FY | 206.21 Thousand USD | 236.34% |
| 2022 Q2 | -1.5 Million USD | 26.48% |
| 2022 FY | -151.25 Thousand USD | 97.45% |
| 2022 Q4 | -151.25 Thousand USD | 82.9% |
| 2022 Q3 | -884.53 Thousand USD | 41.41% |
| 2022 Q1 | -2.05 Million USD | 65.38% |
| 2021 FY | -5.93 Million USD | -368.19% |
| 2021 Q3 | -10.2 Million USD | 13.3% |
| 2021 Q4 | -5.93 Million USD | 41.89% |
| 2021 Q2 | -11.77 Million USD | -702.74% |
| 2021 Q1 | 1.95 Million USD | 254.18% |
| 2020 FY | -1.26 Million USD | -351.37% |
| 2020 Q4 | -1.26 Million USD | 0.0% |
| 2019 FY | -280.65 Thousand USD | 31.68% |
| 2018 FY | -410.78 Thousand USD | -4898.67% |
| 2017 FY | -8217.95 USD | -33.39% |
| 2016 FY | -6161.05 USD | -139.74% |
| 2015 FY | -2569.85 USD | 91.31% |
| 2014 FY | -29.57 Thousand USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1310.00 USD | 15841.756% |
| Arch Therapeutics, Inc. | 5.64 Million USD | 96.349% |
| Evofem Biosciences, Inc. | 42.79 Million USD | 99.518% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | 182.612% |
| Rebus Holdings, Inc. | 305 Thousand USD | 32.388% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | 103.271% |
| Qrons Inc. | 351.42 Thousand USD | 41.32% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 622.36 Thousand USD | 66.866% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | 99.525% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | 1110.471% |
| Skye Bioscience, Inc. | -5.72 Million USD | 103.604% |
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | 98.692% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | 94.992% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | 48.683% |
| SQZ Biotechnologies Company | -36.23 Million USD | 100.569% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | 90.803% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | 77.759% |
| Mesoblast Limited | 55.85 Million USD | 99.631% |
| Marizyme, Inc. | 18.56 Million USD | 98.889% |
| Genus plc | 190.6 Million USD | 99.892% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | 90.777% |
| Pharming Group N.V. | 109.8 Million USD | 99.812% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | 76.028% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | 83.012% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | 69.674% |
| ContraFect Corporation | -6.02 Million USD | 103.422% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | -53.163% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | 82.152% |
| IMV Inc. | 7.67 Million USD | 97.312% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | 96.252% |
| MultiCell Technologies, Inc. | 90.04 USD | -228928.21% |
| ONE Bio Corp. | 9.04 Million USD | 97.719% |
| Accustem Sciences Inc. | -733.97 Thousand USD | 128.096% |
| RVL Pharmaceuticals plc | 12.94 Million USD | 98.407% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 1.36 Million USD | 84.925% |
| Q BioMed Inc. | 4.06 Million USD | 94.921% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | 99.325% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | 79.536% |
| Biomind Labs Inc. | 711.4 Thousand USD | 71.013% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | 99.659% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | 89.686% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | 98.39% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | 42.671% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | -47.504% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | -937.988% |
| Curative Biotechnology, Inc. | 2.2 Million USD | 90.635% |
| GB Sciences, Inc. | 1.74 Million USD | 88.198% |
| Alpha Cognition Inc. | -183.78 Thousand USD | 212.204% |
| HST Global, Inc. | 96.79 Thousand USD | -113.049% |
| CSL Limited | 10.52 Billion USD | 99.998% |
| Halberd Corporation | 144.72 Thousand USD | -42.493% |
| Enzolytics Inc. | 981.65 Thousand USD | 78.993% |
| Agentix Corp. | 37.63 Thousand USD | -447.998% |
| Resverlogix Corp. | 6.45 Million USD | 96.803% |
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | 130.637% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | -2.02 Billion USD | 100.01% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | 100.439% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 97.084% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 92.387% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | 102.333% |
| AVAX Technologies, Inc. | -5.9 Million USD | 103.493% |
| Zenith Capital Corp. | 10.06 Thousand USD | -1949.056% |
| Genscript Biotech Corporation | -1.06 Billion USD | 100.019% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | -2.886% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | 91.357% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | -25.353% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | 1225.762% |
| Kadimastem Ltd | -253.1 Thousand USD | 181.476% |
| Helix BioMedix, Inc. | -2.57 Million USD | 108.024% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.27 Million USD | 98.983% |
| BioStem Technologies, Inc. | 4.47 Million USD | 95.389% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 201.25 Thousand USD | -2.466% |
| LadRx Corporation | -2.03 Million USD | 110.126% |
| Cell Source, Inc. | 9.23 Million USD | 97.766% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 67.533% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 67.533% |
| NovAccess Global Inc. | 2.17 Million USD | 90.534% |
| Affymax, Inc. | -5.59 Million USD | 103.684% |
| Itoco Inc. | 228.3 Thousand USD | 9.675% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | -51.642% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | 95.84% |
| Mobile Lads Corp. | 484.23 Thousand USD | 57.414% |
| CytoDyn Inc. | 20.26 Million USD | 98.982% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | -647.00 USD | 31972.798% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | 2324.962% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | 97.324% |
| SYBLEU INC | 473.71 Thousand USD | 56.468% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | 95.373% |
| International Stem Cell Corporation | 2.59 Million USD | 92.038% |
| Bioxytran, Inc. | 1.89 Million USD | 89.14% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -230.407% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | 90.544% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 3.43 Million USD | 93.995% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | 97.589% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 772.6 Thousand USD | 73.309% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | 116.497% |
| Neutra Corp. | 52.18 Thousand USD | -295.15% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | 108.285% |
| PureTech Health plc | -167.19 Million USD | 100.123% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | 184.202% |
| IXICO plc | -4.44 Million USD | 104.64% |
| IntelGenx Technologies Corp. | 13.21 Million USD | 98.44% |
| Gelesis Holdings, Inc. | 54.85 Million USD | 99.624% |
| CSL Limited | 10.52 Billion USD | 99.998% |
| Cellectis S.A. | -43.81 Million USD | 100.471% |